Cogent Biosciences, Inc.
COGT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001622229
In the last 90 days, Cogent Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 322 institutions reported holding it in 13F filings for Q2 2026, worth $7.50B in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Cogent Biosciences, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 181
- −4 vs. Q1 2025
- Shares held
- 135.5M
- +2.04M (+1.5%) vs. Q1 2025
- Total value
- $973.2M
- +$173.6M (+21.7%) vs. Q1 2025
- New holders
- 30
- 79 more added
- Sold out
- 34
- 37 more reduced
1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting COGT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 322 | $7.50B |
| Q1 2026 | 305 | $7.17B |
| Q4 2025 | 267 | $6.18B |
| Q3 2025 | 195 | $2.29B |
| Q2 2025 | 181 | $973.2M |
| Q1 2025 | 186 | $799.6M |
| Q4 2024 | 177 | $949.5M |
| Q3 2024 | 161 | $1.32B |
| Q2 2024 | 149 | $1.02B |
| Q1 2024 | 146 | $734.3M |
| Q4 2023 | 144 | $534.0M |
| Q3 2023 | 135 | $885.8M |
| Q2 2023 | 136 | $1.05B |
| Q1 2023 | 137 | $810.4M |
| Q4 2022 | 135 | $864.1M |
| Q3 2022 | 134 | $1.10B |
| Q2 2022 | 112 | $633.3M |
| Q1 2022 | 86 | $353.6M |
| Q4 2021 | 82 | $385.2M |
| Q3 2021 | 73 | $309.6M |
| Q2 2021 | 69 | $293.7M |
| Q1 2021 | 69 | $303.3M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Cogent Biosciences, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −18,165−100.0% | Sold out |
| Ieq Capital, LLC | 0 | $0 | 0.00% | −16,792−100.0% | Sold out |
| Mesirow Financial Investment Management, Inc. | 0 | $0 | 0.00% | −21,736−100.0% | Sold out |
| Freestone Grove Partners LP | 0 | $0 | 0.00% | −16,511−100.0% | Sold out |
| Forefront Analytics, LLC | 0 | $0 | 0.00% | −14,015−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −10,604−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −10,080−100.0% | Sold out |
| Aster Capital Management (DIFC) Ltd | 0 | $0 | 0.00% | −2,061−100.0% | Sold out |
| Boston Private Wealth LLC | 0 | $0 | 0.00% | −539−100.0% | Sold out |
| True Wealth Design, LLC | 0 | $0 | 0.00% | −277−100.0% | Sold out |
| Aventura Private Wealth, LLC | 0 | $0 | 0.00% | −112−100.0% | Sold out |
| Amundi | 0 | $0 | 0.00% | −123−100.0% | Sold out |
| Fortitude Family Office, LLC | 0 | $0 | 0.00% | −105−100.0% | Sold out |
| Stephens Consulting, LLC | 0 | $0 | 0.00% | −60−100.0% | Sold out |
| Larson Financial Group LLC | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| Lindbrook Capital, LLC | – | – | – | – | Not filed |